P068 Evaluation of the therapeutic potential of metformin-pretreated tonsil-derived mesenchymal stem cells in a chronic colitis model
Lee K.E.*1, Jung S.-A.1, Joo Y.-H.1, Tae C.H.1, Moon C.M.1, Kim S.-E.1, Jung H.-K.1, Shim K.-N.1, Yoo K.1, Yu Y.s.2, Jo I.h.2
1Ewha Womans University School of Medicine, Department of Internal Medicine, Seoul, South Korea 2Ewha Womans University School of Medicine, Department of Molecular Medicine, Seoul, South Korea
Tonsil-derived mesenchymal stem cells (TMSCs), prepared after tonsillectomy in human, have many advantages including a short doubling time, high differentiation capacity, and mixed chimerism property. Metformin has an anti-inflammatory function involving inhibition of signal transducer and activator of transcription (STAT)-3. We aimed to evaluate the anti-inflammatory effect of metformin-pretreated TMSCs in a mouse model of chronic colitis.
The optimal condition under which maximum decrease in STAT-3 level occurs was evaluated
The STAT-3 level was the lowest in TMSCs treated with 1mM metformin for 7 days, and this concentration was selected for the pretreatment. At 30 days after treatment, DAI (5.8±1.3 vs 2.6±1.0 vs 2.3±0.4, mean±standard error mean values for colitis, TMSC, and metformin-pretreated TMSC groups, respectively,
To our knowledge, this was the first study to evaluate the effect of metformin-pretreated TMSCs in a chronic murine colitis model. Based on the several advantages of TMSCs over other mesenchymal stem cells in clinical use and the anti-inflammatory effect of metformin, TMSCs pretreated with metformin have clinical feasibility and favourable therapeutic potential for colitis treatment.